A New Prospect in Retinoid Therapy: Trifarotene

array:24 ["pii" => "S157821902100295X" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.04.005" "estado" => "S300" "fechaPublicacion" => "2021-11-01" "aid" => "2657" "copyright" => "AEDV" "copyrightAnyo" => "2021" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2021;112:869-72" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0001731021001757" "issn" => "00017310" "doi" => "10.1016/j.ad.2021.04.005" "estado" => "S300" "fechaPublicacion" => "2021-11-01" "aid" => "2657" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2021;112:869-72" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "ARTÍCULO DE OPINIÓN" "titulo" => "Trifaroteno: un nuevo protagonista en el panorama retinoide" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "869" "paginaFinal" => "872" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "A New Prospect in Retinoid Therapy: Trifarotene" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Guerra-Tapia, E. González-Guerra" "autores" => array:2 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Guerra-Tapia" ] 1 => array:2 [ "nombre" => "E." "apellidos" => "González-Guerra" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S157821902100295X" "doi" => "10.1016/j.adengl.2021.04.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S157821902100295X?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021001757?idApp=UINPBA000044" "url" => "/00017310/0000011200000010/v1_202111020534/S0001731021001757/v1_202111020534/es/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S1578219021002444" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.09.003" "estado" => "S300" "fechaPublicacion" => "2021-11-01" "aid" => "2669" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2021;112:873-80" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "Original Article" "titulo" => "Cutibacterium acnes tetracycline resistance profile in patients with acne vulgaris, in a Colombian dermatologic center" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "873" "paginaFinal" => "880" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Perfil de resistencia a la tetraciclina de Cutibacterium acnes en pacientes con acné vulgar en un centro dermatológico de Colombia" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "H.J. Castellanos Lorduy, H.C. Pérez Cely, E.J. Casadiego Rincón, S.C. Henao Riveros, C.L. Colorado" "autores" => array:5 [ 0 => array:2 [ "nombre" => "H.J." "apellidos" => "Castellanos Lorduy" ] 1 => array:2 [ "nombre" => "H.C." "apellidos" => "Pérez Cely" ] 2 => array:2 [ "nombre" => "E.J." "apellidos" => "Casadiego Rincón" ] 3 => array:2 [ "nombre" => "S.C." "apellidos" => "Henao Riveros" ] 4 => array:2 [ "nombre" => "C.L." "apellidos" => "Colorado" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731021001915" "doi" => "10.1016/j.ad.2021.05.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021001915?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002444?idApp=UINPBA000044" "url" => "/15782190/0000011200000010/v1_202111080506/S1578219021002444/v1_202111080506/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "Opinion Article" "titulo" => "A New Prospect in Retinoid Therapy: Trifarotene" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "869" "paginaFinal" => "872" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "A. Guerra-Tapia, E. González-Guerra" "autores" => array:2 [ 0 => array:4 [ "nombre" => "A." "apellidos" => "Guerra-Tapia" "email" => array:1 [ 0 => "auroraguerratapia@gmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "E." "apellidos" => "González-Guerra" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Clínica Dermatólogas Guerra, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Universidad Complutense de Madrid, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Hospital Clínico Universitario San Carlos, Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Trifaroteno: un nuevo protagonista en el panorama retinoide" ] ] "textoCompleto" => "Common acne affects approximately 85% of young people, often persisting to adult age.<a class="elsevierStyleCrossRef" href="#bib0005">1</a> It is a chronic inflammatory disease of the pilosebaceous unit and its pathogenesis involves the production of sebum, bacterial colonization by Cutibacterium acnes, and certain keratinization abnormalities.<a class="elsevierStyleCrossRef" href="#bib0010">2</a> Clinical presentation is characterized by the concomitance of open and closed comedos, inflammatory papules, pustules, nodules, and scars,<a class="elsevierStyleCrossRef" href="#bib0005">1</a> which present on the face, and also on the chest and/or back in up to 50% of patients.<a class="elsevierStyleCrossRef" href="#bib0015">3</a> Its active presence and its scars affect the emotional wellbeing and have a detrimental effect on the quality of life and mental state of the patient, leading to depression, social isolation, and suicidal thoughts in a considerable number of cases.<a class="elsevierStyleCrossRef" href="#bib0020">4</a>The principal treatment that has managed, in spectacular form, to reverse most of the negative effects of acne is the use of retinoids. These are structural and functional analogs of vitamin A that can mediate in intranuclear retinoid receptors by activating genes that respond to retinoic acid.<a class="elsevierStyleCrossRef" href="#bib0005">1</a>Systemic retinoids are mostly used in moderate to severe cases or those that have proven refractory to previous treatments.<a class="elsevierStyleCrossRef" href="#bib0015">3</a> The representative par excellence is isotretinoin, the major adverse effect of which is teratogenicity, making prevention of its use in pregnancy essential, regardless of the dose.<a class="elsevierStyleCrossRef" href="#bib0025">5</a> Topical retinoids are used in single-drug therapy or in combination with other molecules, such as benzoyl peroxide, antibiotics, etc., and as maintenance therapy following systemic therapies.<a class="elsevierStyleCrossRef" href="#bib0030">6</a> Its anti-inflammatory, antiseborrheic, and microcomedo-formation limiting properties support its unquestionable efficacy.<a class="elsevierStyleCrossRefs" href="#bib0005">1–6</a>The first generation of retinoids consists of nonaromatic compounds: 12-cis-retinoic acid, all-trans retinoic acid, and 9-cis-retinoic acid, which are derived from vitamin A and present modifications to the terminal polar group and on the polyene chain.<a class="elsevierStyleCrossRef" href="#bib0035">7</a> Second-generation retinoids are characterized by being monoaromatic with modifications to the ring. They are also more lipophilic and have greater bioavailability than those of the previous generation, and include etretinate and acetretin.<a class="elsevierStyleCrossRef" href="#bib0035">7</a> Third-generation retinoids are characterized by their polyaromatic structure (through cyclization of the polyene chain) and their greater rigidity. Examples of this group include adapalene, tazarotene, and bexarotene.<a class="elsevierStyleCrossRef" href="#bib0035">7</a>More than 20 years have passed between the final approval of a new active ingredient against acne and authorization of the sale of trifarotene, a new topical retinoid that inaugurates the 4th generation.<a class="elsevierStyleCrossRef" href="#bib0040">8</a> The US Food and Drug Administration approved this drug in October 2019 (it was later approved by the European Medicines Agency) for use in acne of the face and torso.<a class="elsevierStyleCrossRefs" href="#bib0045">9,10</a> Despite the need for a treatment focusing on the chest and/or back, little scientific evidence has been available to date regarding the management of acne in these locations.<a class="elsevierStyleCrossRefs" href="#bib0055">11–13</a>Trifarotene is a retinoid aimed specifically at the retinoic acid receptor (RAR)-γ (the most common isoform in the skin), with low affinity for RAR-α and RAR-β.<a class="elsevierStyleCrossRef" href="#bib0040">8</a> Its mechanism of action provides it with anti-inflammatory, comedolytic, and depigmenting effects.<a class="elsevierStyleCrossRef" href="#bib0040">8</a> This last property was shown in preclinical trials in SKH2 mice.<a class="elsevierStyleCrossRef" href="#bib0070">14</a> Depigmenting activity in the tails of mice was compared using topical adapalene 0.1%, trifarotene 0.01%, and all-trans retinoic acid 0.1%, daily for 6 weeks. The last 2 drugs showed significant activity, whereas adapalene (possibly due to its lesser penetration in the skin) did not produce significant depigmentation.<a class="elsevierStyleCrossRef" href="#bib0070">14</a>The efficacy and safety of topical trifarotene 50 μg/g was evaluated in 2 pivotal randomized, double-blind vehicle-controlled (1:1) phase-III clinical trials (PERFECT 1, PERFECT 2). Patients over 9 years of age (n = 1208 and 1212, respectively) received the topical retinoid on the face and torso for 12 weeks.<a class="elsevierStyleCrossRef" href="#bib0075">15</a> The primary objectives in both trials were efficacy on the face, measured using the investigator global assessment scale, as a degree of improvement of 2 or more points, and the change from the baseline status to the status at week 12 with regard to inflammatory and noninflammatory lesions. The secondary objectives focused on efficiency on the torso evaluated by means of the physician global assessment, and the change in the number of acne lesions. The primary and secondary objectives were achieved in both studies with statistical significance (P < .001) in favor of trifarotene, as shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.<a class="elsevierStyleCrossRef" href="#bib0075">15</a> Onset of the effect of trifarotene was rapid and a reduction in the acne lesions occurred from the 1st week of use in the case of the face and the 2nd week in the case of treatment of the torso.<a class="elsevierStyleCrossRef" href="#bib0075">15</a> With regard to the safety profile, the adverse effects associated with the drug were mainly cutaneous and occurred at the application site. Suspension of treatment was notified in 1.9% and 1.2% of the participants in the PERFECT 1 and PERFECT 2 trials, respectively, due to irritation at the site of application and allergic dermatitis.<a class="elsevierStyleCrossRef" href="#bib0075">15</a><elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Blume-Peytavi et al<a class="elsevierStyleCrossRef" href="#bib0080">16</a> carried out a long-term open trial over 52 weeks. The study was completed by 75.5% of the initially enrolled participants (n = 342/453, <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Adverse effects associated with the drug were notified in 12.6% of patients and none of the effects was severe. The efficacy rates, measured using the investigator global assessment scale and the physician global assessment, increased from week 12 to week 52, reaching values of 65.1% and 66.9%, respectively. In week 52, 53.8% of patients stated that the acne was not affecting their quality of life.<a class="elsevierStyleCrossRef" href="#bib0080">16</a>Case series in real clinical practice have also been published in the literature. Johnson et al<a class="elsevierStyleCrossRef" href="#bib0085">17</a> published an intermediate analysis at 12 weeks (total duration of 24 weeks), in which 3 patients with acne of the face and torso, with more than 20 lesions in each area, were treated.<a class="elsevierStyleCrossRef" href="#bib0085">17</a> The patients stated their satisfaction with efficacy in both areas, ease of use, and time to onset of improvement. Moreover, tolerability of the product was favorable. All the above key points of treatment with trifarotene are summarized in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>.<elsevierMultimedia ident="tbl0010"></elsevierMultimedia>Scientific evidence continues to be generated on the use of trifarotene.<a class="elsevierStyleCrossRef" href="#bib0040">8</a> Clinical trials are focusing on determining the results notified by patients (clinical trial identifier: NCT03915860) and on studying the profile of the drug in combination with oral antibiotics, in cases of severe acne (clinical trial identifier: NCT04451330).Trifarotene is the first therapeutic novelty in the area of acne in decades. Its arrival has been well received by physicians and by patients, who in many cases needed an alternative to the available treatments. One of the key points is its specific indication for acne on the torso. With regard to this aspect, many patients state that, in general, application of topical treatments on the chest and/or back is complicated and they are sometimes reticent about asking for help. The vehicle used in the formulation of trifarotene, however, makes its use on large areas easy and only a small amount of product is required to cover the entire area.All the safety and efficacy data on treatment published in the literature are in agreement with what we have been able to observe in our clinic.In our clinical experience, patients also value the rapid onset of action of this drug. This is very important because it increases adherence to treatment, which tends to be low in this group of patients.<a class="elsevierStyleCrossRef" href="#bib0090">18</a> It should be mentioned, however, that starting treatment with trifarotene should be undertaken with care. Some patients complain of having suffered from flaking, dryness, or erythema. Nevertheless, these adverse effects can be managed effectively with the use of an appropriate moisturizer or by spacing the initial applications until the frequency of continued application is achieved. Trifarotene also metabolized well, avoiding the problem of bioaccumulation in the body. Altogether, this topical retinoid has been shown to be effective and safe in patients refractory to currently available topical treatments and achieves a good response with considerable reduction in acne lesions.Trifarotene is the first therapeutic novelty in the Spanish market in 20 years. Based on the available scientific evidence and on our clinical experience, trifarotene is effective and safe for the treatment of acne on the face and torso. This drug provides added value in several aspects: ease of application, speed of action, and use on large areas, with the resulting improvement in the quality of life of the patients, and their adherence to and satisfaction with the treatment." "pdfFichero" => "main.pdf" "tienePdf" => true "fechaAceptado" => "2021-04-25" "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Guerra-Tapia A, González-Guerra E. Trifaroteno: un nuevo protagonista en el panorama retinoide. Actas Dermosifiliogr. 2021;112:869–872." ] ] "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Abbreviations: IGA indicates investigator global assessment scale; NR, not reported; PGA, physician global assessment scale." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">PERFECT 1<a class="elsevierStyleCrossRef" href="#bib0075">15</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">PERFECT 2<a class="elsevierStyleCrossRef" href="#bib0075">15</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Long-term study<a class="elsevierStyleCrossRef" href="#bib0080">16</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1208 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1212 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">453 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Design \t\t\t\t\t\t\n \t\t\t\t</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_colgroup " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pivotal randomized, double-blind vehicle-controlled (1:1) phase-III clinical trials; duration 12 weeks</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Phase-III, multicenter, open, noncomparative trial; duration 52 weeks \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Drug \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Trifarotene vs. vehicle \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Trifarotene vs. vehicle \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Trifarotene \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Efficacy on the face \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IGA score (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">29.4 vs. 19.5 (P < .001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42.3 vs. 25.7 (P< .001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">65.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Inflammatory lesions, absolute change from baseline status, n \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">−19.0 vs. − 15.4 (P < .001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-24.2 vs. 18.7 (P < .001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NR \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Noninflammatory lesions, absolute change from baseline status, n \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-25.0 vs. -17.9 (P < .001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-30.1 vs. -21.6 (P < .001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NR \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Efficacy on the torso \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PGA score (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">35.7 vs. 25.0 (P < .001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42.6 vs. 29.9 (P < .001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">66.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Inflammatory lesions, absolute change from baseline status, n \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-21.4 vs. -18.8 (P < .001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-25.5 vs. -19.8 (P < .001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NR \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Noninflammatory lesions, absolute change from baseline status, n \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-21.9 vs. -17.8 (P < .001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-25.9 vs. -20.8 (P < .001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NR \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Safety \t\t\t\t\t\t\n \t\t\t\t</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_colgroup " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cutaneous reactions at application site</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Severe in 6 patients: skin irritation, sunburn, allergic dermatitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Severe in 3 patients: pain, erosion, irritation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate: 4.6% pruritus; 4.2% irritation; 1.8% sunburn \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Interruption, % \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2740419.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Summary of Publications Regarding Scientific Evidence on Trifarotene." ] ] 1 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Abbreviations: IGA indicates investigator global assessment scale; PGA, physician global assessment scale." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">First therapeutic novelty approved in more than 20 years<a class="elsevierStyleCrossRef" href="#bib0040">8</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Indication for acne on the face and torso (chest/back)<a class="elsevierStyleCrossRef" href="#bib0050">10</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rapid onset of action, from the 1st week in use on the face and 2nd week in application on the torso<a class="elsevierStyleCrossRef" href="#bib0075">15</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adherence greater than 75% after 52 weeks of use<a class="elsevierStyleCrossRef" href="#bib0080">16</a> and interruption below 2% after 12 weeks<a class="elsevierStyleCrossRef" href="#bib0075">15</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ease of use reported by patients<a class="elsevierStyleCrossRef" href="#bib0085">17</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Scientific evidence verified at 12 and 52 weeks, on the face and on the torso, by means of the IGA/IPA scales and lesion count<a class="elsevierStyleCrossRefs" href="#bib0075">15,16</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Associated cutaneous adverse effects, mostly at the application site<a class="elsevierStyleCrossRef" href="#bib0075">15</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2740418.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Key points of treatment with trifarotene." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:18 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Retinoids in acne management: review of current understanding, future considerations, and focus on topical treatments" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A. Chien" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Drugs Dermatol" "fecha" => "2018" "volumen" => "17" "paginaInicial" => "s51" "paginaFinal" => "s55" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30586483" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Modern management of acne" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.J. Cooper" 1 => "V.R. Harris" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5694/mja16.00516" "Revista" => array:6 [ "tituloSerie" => "Med J Aust" "fecha" => "2017" "volumen" => "206" "paginaInicial" => "41" "paginaFinal" => "45" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28076744" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.Q. Del Rosso" 1 => "J.B. Bikowski" 2 => "E. Baum" 3 => "J. Smith" 4 => "S. Hawkes" 5 => "V. Benes" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Drugs Dermatol" "fecha" => "2007" "volumen" => "6" "paginaInicial" => "597" "paginaFinal" => "600" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17668525" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acne and quality of life - impact and management" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "U. Gieler" 1 => "T. Gieler" 2 => "J.P. Kupfer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jdv.13191" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2015" "volumen" => "29" "paginaInicial" => "12" "paginaFinal" => "14" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26059729" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Challenges and solutions in oral isotretinoin in acne: reflections on 35 years of experience" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "V. Bettoli" 1 => "A. Guerra-Tapia" 2 => "M.I. Herane" 3 => "J. Piquero-Martín" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/CCID.S234231" "Revista" => array:6 [ "tituloSerie" => "Clin Cosmet Investig Dermatol" "fecha" => "2019" "volumen" => "12" "paginaInicial" => "943" "paginaFinal" => "951" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32021364" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment modalities for Acne" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "L. Fox" 1 => "C. Csongradi" 2 => "M. Aucamp" 3 => "J. du Plessis" 4 => "M. Gerber" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/molecules21081063" "Revista" => array:4 [ "tituloSerie" => "Molecules" "fecha" => "2016" "volumen" => "21" "paginaInicial" => "1063" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Khalil" 1 => "T. Bardawil" 2 => "C. Stephan" 3 => "N. Darwiche" 4 => "O. Abbas" 5 => "A.G. Kibbi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/09546634.2017.1309349" "Revista" => array:6 [ "tituloSerie" => "J Dermatolog Treat" "fecha" => "2017" "volumen" => "28" "paginaInicial" => "684" "paginaFinal" => "696" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28318351" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trifarotene: a current review and perspectives in dermatology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:8 [ 0 => "T. Cosio" 1 => "M. Di Prete" 2 => "R. Gaziano" 3 => "C. Lanna" 4 => "A. Orlandi" 5 => "P. Di Francesco" 6 => "L. Bianchi" 7 => "E. Campione" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/biomedicines9030237" "Revista" => array:5 [ "tituloSerie" => "Biomedicines" "fecha" => "2021" "volumen" => "9" "paginaInicial" => "237" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33652835" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "U.S. Food and Drug Administration. Novel drug approvals for 2019. Silver Spring: FDA; 2019. Available from: <a target="_blank" href="https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019">https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019</a>. [Accessed 8 March 2021]." ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Heads of Medicine Agencies. Details of Product Name in the RMS: Aklief. Available from: <a target="_blank" href="https://mri.cts-mrp.eu/Human/Product/Details/58971">https://mri.cts-mrp.eu/Human/Product/Details/58971</a>. [Accessed 25 May 2021]." ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of acne: Canadian clinical practice guideline" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Asai" 1 => "A. Baibergenova" 2 => "M. Dutil" 3 => "S. Humphrey" 4 => "P. Hull" 5 => "C. Lynde" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1503/cmaj.140665" "Revista" => array:6 [ "tituloSerie" => "CMAJ" "fecha" => "2016" "volumen" => "188" "paginaInicial" => "118" "paginaFinal" => "126" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26573753" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Understanding truncal acne: a practical guide to diagnosis and management" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C.W. Liu" 1 => "J. Tan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Skin Therapy Lett" "fecha" => "2017" "volumen" => "12" "paginaInicial" => "1" "paginaFinal" => "7" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18227953" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Truncal acne, what do we know?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "B. Dréno" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jdv.16634" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2020" "volumen" => "34" "paginaInicial" => "2241" "paginaFinal" => "2246" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32421879" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Aubert" 1 => "D. Piwnica" 2 => "B. Bertino" 3 => "S. Blanchet-Réthoré" 4 => "I. Carlavan" 5 => "S. Déret" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.16719" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2018" "volumen" => "179" "paginaInicial" => "442" "paginaFinal" => "456" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29974453" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Tan" 1 => "D. Thiboutot" 2 => "G. Popp" 3 => "M. Gooderham" 4 => "C. Lynde" 5 => "J. Del Rosso" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2019.02.044" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2019" "volumen" => "80" "paginaInicial" => "1691" "paginaFinal" => "1699" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30802558" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "U. Blume-Peytavi" 1 => "J. Fowler" 2 => "L. Kemény" 3 => "Z. Draelos" 4 => "F. Cook-Bolden" 5 => "T. Dirschka" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jdv.15794" "Revista" => array:5 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2020" "volumen" => "34" "paginaInicial" => "166" "paginaFinal" => "173" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Subject satisfaction with trifarotene 50 μg/g cream in the treatment of facial and truncal acne vulgaris: a case series" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S.M. Johnson" 1 => "R. Chavda" 2 => "J.C. DuBois" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s13555-020-00417-4" "Revista" => array:5 [ "tituloSerie" => "Dermatol Ther (Heidelb)" "fecha" => "2020" "volumen" => "10" "paginaInicial" => "1165" "paginaFinal" => "1173" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "How to increase adherence and compliance in acne treatment? A combined strategy of SMS and visual instruction leaflet" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Donnarumma" 1 => "D. Fattore" 2 => "V. Greco" 3 => "M. Ferrillo" 4 => "M. Vastarella" 5 => "P. Chiodini" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000502575" "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "2019" "volumen" => "235" "paginaInicial" => "463" "paginaFinal" => "470" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31586999" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack566195" "titulo" => "Acknowledgments" "texto" => "The authors would like to thank Sonia Romero (scientific advisor, Meisys) for her support in writing this article." "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011200000010/v1_202111080506/S157821902100295X/v1_202111080506/en/main.assets" "Apartado" => array:4 [ "identificador" => "6152" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Opinion Article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011200000010/v1_202111080506/S157821902100295X/v1_202111080506/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S157821902100295X?idApp=UINPBA000044"]

Statistics

Opinion Article

A New Prospect in Retinoid Therapy: Trifarotene

Trifaroteno: un nuevo protagonista en el panorama retinoide

A. Guerra-Tapiaa,b,

Corresponding author

auroraguerratapia@gmail.com

Corresponding author.

, E. González-Guerraa,b,c

a Clínica Dermatólogas Guerra, Madrid, Spain

b Universidad Complutense de Madrid, Madrid, Spain

c Hospital Clínico Universitario San Carlos, Madrid, Spain

Read

5906

Times
was read the article

1871

Total PDF

4035

Total HTML

Share statistics

 array:24 [
  "pii" => "S157821902100295X"
  "issn" => "15782190"
  "doi" => "10.1016/j.adengl.2021.04.005"
  "estado" => "S300"
  "fechaPublicacion" => "2021-11-01"
  "aid" => "2657"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2021"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "sco"
  "cita" => "Actas Dermosifiliogr. 2021;112:869-72"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:20 [
      "pii" => "S0001731021001757"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2021.04.005"
      "estado" => "S300"
      "fechaPublicacion" => "2021-11-01"
      "aid" => "2657"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "sco"
      "cita" => "Actas Dermosifiliogr. 2021;112:869-72"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">ART&#205;CULO DE OPINI&#211;N</span>"
        "titulo" => "Trifaroteno&#58; un nuevo protagonista en el panorama retinoide"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "869"
            "paginaFinal" => "872"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "A New Prospect in Retinoid Therapy&#58; Trifarotene"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "A&#46; Guerra-Tapia, E&#46; Gonz&#225;lez-Guerra"
            "autores" => array:2 [
              0 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Guerra-Tapia"
              ]
              1 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Gonz&#225;lez-Guerra"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S157821902100295X"
          "doi" => "10.1016/j.adengl.2021.04.005"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S157821902100295X?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021001757?idApp=UINPBA000044"
      "url" => "/00017310/0000011200000010/v1_202111020534/S0001731021001757/v1_202111020534/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:20 [
    "pii" => "S1578219021002444"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2021.09.003"
    "estado" => "S300"
    "fechaPublicacion" => "2021-11-01"
    "aid" => "2669"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2021;112:873-80"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "<span class="elsevierStyleItalic">Cutibacterium acnes</span> tetracycline resistance profile in patients with acne vulgaris&#44; in a Colombian dermatologic center"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "873"
          "paginaFinal" => "880"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Perfil de resistencia a la tetraciclina de <span class="elsevierStyleItalic">Cutibacterium acnes</span> en pacientes con acn&#233; vulgar en un centro dermatol&#243;gico de Colombia"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "H&#46;J&#46; Castellanos Lorduy, H&#46;C&#46; P&#233;rez Cely, E&#46;J&#46; Casadiego Rinc&#243;n, S&#46;C&#46; Henao Riveros, C&#46;L&#46; Colorado"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "H&#46;J&#46;"
              "apellidos" => "Castellanos Lorduy"
            ]
            1 => array:2 [
              "nombre" => "H&#46;C&#46;"
              "apellidos" => "P&#233;rez Cely"
            ]
            2 => array:2 [
              "nombre" => "E&#46;J&#46;"
              "apellidos" => "Casadiego Rinc&#243;n"
            ]
            3 => array:2 [
              "nombre" => "S&#46;C&#46;"
              "apellidos" => "Henao Riveros"
            ]
            4 => array:2 [
              "nombre" => "C&#46;L&#46;"
              "apellidos" => "Colorado"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0001731021001915"
        "doi" => "10.1016/j.ad.2021.05.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021001915?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002444?idApp=UINPBA000044"
    "url" => "/15782190/0000011200000010/v1_202111080506/S1578219021002444/v1_202111080506/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Opinion Article</span>"
    "titulo" => "A New Prospect in Retinoid Therapy&#58; Trifarotene"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "869"
        "paginaFinal" => "872"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "A&#46; Guerra-Tapia, E&#46; Gonz&#225;lez-Guerra"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "A&#46;"
            "apellidos" => "Guerra-Tapia"
            "email" => array:1 [
              0 => "auroraguerratapia@gmail.com"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "&#42;"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "E&#46;"
            "apellidos" => "Gonz&#225;lez-Guerra"
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:3 [
          0 => array:3 [
            "entidad" => "Cl&#237;nica Dermat&#243;logas Guerra&#44; Madrid&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Universidad Complutense de Madrid&#44; Madrid&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Hospital Cl&#237;nico Universitario San Carlos&#44; Madrid&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Trifaroteno&#58; un nuevo protagonista en el panorama retinoide"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Common acne affects approximately 85&#37; of young people&#44; often persisting to adult age&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> It is a chronic inflammatory disease of the pilosebaceous unit and its pathogenesis involves the production of sebum&#44; bacterial colonization by <span class="elsevierStyleItalic">Cutibacterium acnes</span>&#44; and certain keratinization abnormalities&#46;<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> Clinical presentation is characterized by the concomitance of open and closed comedos&#44; inflammatory papules&#44; pustules&#44; nodules&#44; and scars&#44;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> which present on the face&#44; and also on the chest and&#47;or back in up to 50&#37; of patients&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> Its active presence and its scars affect the emotional wellbeing and have a detrimental effect on the quality of life and mental state of the patient&#44; leading to depression&#44; social isolation&#44; and suicidal thoughts in a considerable number of cases&#46;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The principal treatment that has managed&#44; in spectacular form&#44; to reverse most of the negative effects of acne is the use of retinoids&#46; These are structural and functional analogs of vitamin A that can mediate in intranuclear retinoid receptors by activating genes that respond to retinoic acid&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Systemic retinoids are mostly used in moderate to severe cases or those that have proven refractory to previous treatments&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> The representative <span class="elsevierStyleItalic">par excellence</span> is isotretinoin&#44; the major adverse effect of which is teratogenicity&#44; making prevention of its use in pregnancy essential&#44; regardless of the dose&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> Topical retinoids are used in single-drug therapy or in combination with other molecules&#44; such as benzoyl peroxide&#44; antibiotics&#44; etc&#46;&#44; and as maintenance therapy following systemic therapies&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> Its anti-inflammatory&#44; antiseborrheic&#44; and microcomedo-formation limiting properties support its unquestionable efficacy&#46;<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1&#8211;6</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">The first generation of retinoids consists of nonaromatic compounds&#58; 12-cis-retinoic acid&#44; all-trans retinoic acid&#44; and 9-cis-retinoic acid&#44; which are derived from vitamin A and present modifications to the terminal polar group and on the polyene chain&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> Second-generation retinoids are characterized by being monoaromatic with modifications to the ring&#46; They are also more lipophilic and have greater bioavailability than those of the previous generation&#44; and include etretinate and acetretin&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> Third-generation retinoids are characterized by their polyaromatic structure &#40;through cyclization of the polyene chain&#41; and their greater rigidity&#46; Examples of this group include adapalene&#44; tazarotene&#44; and bexarotene&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">More than 20 years have passed between the final approval of a new active ingredient against acne and authorization of the sale of trifarotene&#44; a new topical retinoid that inaugurates the 4<span class="elsevierStyleSup">th</span> generation&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> The US Food and Drug Administration approved this drug in October 2019 &#40;it was later approved by the European Medicines Agency&#41; for use in acne of the face and torso&#46;<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9&#44;10</span></a> Despite the need for a treatment focusing on the chest and&#47;or back&#44; little scientific evidence has been available to date regarding the management of acne in these locations&#46;<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">11&#8211;13</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Trifarotene is a retinoid aimed specifically at the retinoic acid receptor &#40;RAR&#41;-&#947; &#40;the most common isoform in the skin&#41;&#44; with low affinity for RAR-&#945; and RAR-&#946;&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> Its mechanism of action provides it with anti-inflammatory&#44; comedolytic&#44; and depigmenting effects&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> This last property was shown in preclinical trials in SKH2 mice&#46;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> Depigmenting activity in the tails of mice was compared using topical adapalene 0&#46;1&#37;&#44; trifarotene 0&#46;01&#37;&#44; and all-trans retinoic acid 0&#46;1&#37;&#44; daily for 6 weeks&#46; The last 2 drugs showed significant activity&#44; whereas adapalene &#40;possibly due to its lesser penetration in the skin&#41; did not produce significant depigmentation&#46;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">The efficacy and safety of topical trifarotene 50&#160;&#956;g&#47;g was evaluated in 2 pivotal randomized&#44; double-blind vehicle-controlled &#40;1&#58;1&#41; phase-III clinical trials &#40;PERFECT 1&#44; PERFECT 2&#41;&#46; Patients over 9 years of age &#40;n&#160;&#61;&#160;1208 and 1212&#44; respectively&#41; received the topical retinoid on the face and torso for 12 weeks&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> The primary objectives in both trials were efficacy on the face&#44; measured using the investigator global assessment scale&#44; as a degree of improvement of 2 or more points&#44; and the change from the baseline status to the status at week 12 with regard to inflammatory and noninflammatory lesions&#46; The secondary objectives focused on efficiency on the torso evaluated by means of the physician global assessment&#44; and the change in the number of acne lesions&#46; The primary and secondary objectives were achieved in both studies with statistical significance &#40;<span class="elsevierStyleItalic">P</span>&#160;&#60;&#160;&#46;001&#41; in favor of trifarotene&#44; as shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> Onset of the effect of trifarotene was rapid and a reduction in the acne lesions occurred from the 1st week of use in the case of the face and the 2nd week in the case of treatment of the torso&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> With regard to the safety profile&#44; the adverse effects associated with the drug were mainly cutaneous and occurred at the application site&#46; Suspension of treatment was notified in 1&#46;9&#37; and 1&#46;2&#37; of the participants in the PERFECT 1 and PERFECT 2 trials&#44; respectively&#44; due to irritation at the site of application and allergic dermatitis&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">Blume-Peytavi et al<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> carried out a long-term open trial over 52 weeks&#46; The study was completed by 75&#46;5&#37; of the initially enrolled participants &#40;n&#160;&#61;&#160;342&#47;453&#44; <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; Adverse effects associated with the drug were notified in 12&#46;6&#37; of patients and none of the effects was severe&#46; The efficacy rates&#44; measured using the investigator global assessment scale and the physician global assessment&#44; increased from week 12 to week 52&#44; reaching values of 65&#46;1&#37; and 66&#46;9&#37;&#44; respectively&#46; In week 52&#44; 53&#46;8&#37; of patients stated that the acne was not affecting their quality of life&#46;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">Case series in real clinical practice have also been published in the literature&#46; Johnson et al<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> published an intermediate analysis at 12 weeks &#40;total duration of 24 weeks&#41;&#44; in which 3 patients with acne of the face and torso&#44; with more than 20 lesions in each area&#44; were treated&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> The patients stated their satisfaction with efficacy in both areas&#44; ease of use&#44; and time to onset of improvement&#46; Moreover&#44; tolerability of the product was favorable&#46; All the above key points of treatment with trifarotene are summarized in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0050" class="elsevierStylePara elsevierViewall">Scientific evidence continues to be generated on the use of trifarotene&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> Clinical trials are focusing on determining the results notified by patients &#40;clinical trial identifier&#58; NCT03915860&#41; and on studying the profile of the drug in combination with oral antibiotics&#44; in cases of severe acne &#40;clinical trial identifier&#58; NCT04451330&#41;&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">Trifarotene is the first therapeutic novelty in the area of acne in decades&#46; Its arrival has been well received by physicians and by patients&#44; who in many cases needed an alternative to the available treatments&#46; One of the key points is its specific indication for acne on the torso&#46; With regard to this aspect&#44; many patients state that&#44; in general&#44; application of topical treatments on the chest and&#47;or back is complicated and they are sometimes reticent about asking for help&#46; The vehicle used in the formulation of trifarotene&#44; however&#44; makes its use on large areas easy and only a small amount of product is required to cover the entire area&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">All the safety and efficacy data on treatment published in the literature are in agreement with what we have been able to observe in our clinic&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">In our clinical experience&#44; patients also value the rapid onset of action of this drug&#46; This is very important because it increases adherence to treatment&#44; which tends to be low in this group of patients&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> It should be mentioned&#44; however&#44; that starting treatment with trifarotene should be undertaken with care&#46; Some patients complain of having suffered from flaking&#44; dryness&#44; or erythema&#46; Nevertheless&#44; these adverse effects can be managed effectively with the use of an appropriate moisturizer or by spacing the initial applications until the frequency of continued application is achieved&#46; Trifarotene also metabolized well&#44; avoiding the problem of bioaccumulation in the body&#46; Altogether&#44; this topical retinoid has been shown to be effective and safe in patients refractory to currently available topical treatments and achieves a good response with considerable reduction in acne lesions&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">Trifarotene is the first therapeutic novelty in the Spanish market in 20 years&#46; Based on the available scientific evidence and on our clinical experience&#44; trifarotene is effective and safe for the treatment of acne on the face and torso&#46; This drug provides added value in several aspects&#58; ease of application&#44; speed of action&#44; and use on large areas&#44; with the resulting improvement in the quality of life of the patients&#44; and their adherence to and satisfaction with the treatment&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaAceptado" => "2021-04-25"
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Guerra-Tapia A&#44; Gonz&#225;lez-Guerra E&#46; Trifaroteno&#58; un nuevo protagonista en el panorama retinoide&#46; Actas Dermosifiliogr&#46; 2021&#59;112&#58;869&#8211;872&#46;</p>"
      ]
    ]
    "multimedia" => array:2 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; IGA indicates investigator global assessment scale&#59; NR&#44; not reported&#59; PGA&#44; physician global assessment scale&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">PERFECT 1<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">PERFECT 2<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Long-term study<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">N</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1208&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1212&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">453&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Design</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_colgroup " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pivotal randomized&#44; double-blind vehicle-controlled &#40;1&#58;1&#41; phase-III clinical trials&#59; duration 12 weeks</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Phase-III&#44; multicenter&#44; open&#44; noncomparative trial&#59; duration 52 weeks&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Drug</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Trifarotene vs&#46; vehicle&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Trifarotene vs&#46; vehicle&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Trifarotene&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Efficacy on the face</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>IGA score &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">29&#46;4 vs&#46; 19&#46;5 &#40;<span class="elsevierStyleItalic">P</span>&#160;&#60;&#160;&#46;001&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">42&#46;3 vs&#46; 25&#46;7 &#40;<span class="elsevierStyleItalic">P</span>&#60;&#160;&#46;001&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">65&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Inflammatory lesions&#44; absolute change from baseline status&#44; n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8722;19&#46;0 vs&#46;&#160;&#8722;&#160;15&#46;4 &#40;<span class="elsevierStyleItalic">P</span>&#160;&#60;&#160;&#46;001&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-24&#46;2 vs&#46; 18&#46;7 &#40;<span class="elsevierStyleItalic">P</span>&#160;&#60;&#160;&#46;001&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Noninflammatory lesions&#44; absolute change from baseline status&#44; n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-25&#46;0 vs&#46; -17&#46;9 &#40;<span class="elsevierStyleItalic">P</span>&#160;&#60;&#160;&#46;001&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-30&#46;1 vs&#46; -21&#46;6 &#40;<span class="elsevierStyleItalic">P</span>&#160;&#60;&#160;&#46;001&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Efficacy on the torso</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>PGA score &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">35&#46;7 vs&#46; 25&#46;0 &#40;<span class="elsevierStyleItalic">P</span>&#160;&#60;&#160;&#46;001&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">42&#46;6 vs&#46; 29&#46;9 &#40;<span class="elsevierStyleItalic">P</span>&#160;&#60;&#160;&#46;001&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">66&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Inflammatory lesions&#44; absolute change from baseline status&#44; n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-21&#46;4 vs&#46; -18&#46;8 &#40;<span class="elsevierStyleItalic">P</span>&#160;&#60;&#160;&#46;001&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-25&#46;5 vs&#46; -19&#46;8 &#40;<span class="elsevierStyleItalic">P</span>&#160;&#60;&#160;&#46;001&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Noninflammatory lesions&#44; absolute change from baseline status&#44; n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-21&#46;9 vs&#46; -17&#46;8 &#40;<span class="elsevierStyleItalic">P</span>&#160;&#60;&#160;&#46;001&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-25&#46;9 vs&#46; -20&#46;8 &#40;<span class="elsevierStyleItalic">P</span>&#160;&#60;&#160;&#46;001&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Safety</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_colgroup " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cutaneous reactions at application site</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Severe in 6 patients&#58; skin irritation&#44; sunburn&#44; allergic dermatitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Severe in 3 patients&#58; pain&#44; erosion&#44; irritation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate&#58; 4&#46;6&#37; pruritus&#59; 4&#46;2&#37; irritation&#59; 1&#46;8&#37; sunburn&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Interruption&#44; &#37;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2740419.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Summary of Publications Regarding Scientific Evidence on Trifarotene&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0010"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; IGA indicates investigator global assessment scale&#59; PGA&#44; physician global assessment scale&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">First therapeutic novelty approved in more than 20 years<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Indication for acne on the face and torso &#40;chest&#47;back&#41;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rapid onset of action&#44; from the 1<span class="elsevierStyleSup">st</span> week in use on the face and 2nd week in application on the torso<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Adherence greater than 75&#37; after 52 weeks of use<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> and interruption below 2&#37; after 12 weeks<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ease of use reported by patients<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Scientific evidence verified at 12 and 52 weeks&#44; on the face and on the torso&#44; by means of the IGA&#47;IPA scales and lesion count<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15&#44;16</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Associated cutaneous adverse effects&#44; mostly at the application site<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2740418.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Key points of treatment with trifarotene&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:18 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Retinoids in acne management&#58; review of current understanding&#44; future considerations&#44; and focus on topical treatments"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "A&#46; Chien"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Drugs Dermatol"
                        "fecha" => "2018"
                        "volumen" => "17"
                        "paginaInicial" => "s51"
                        "paginaFinal" => "s55"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30586483"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Modern management of acne"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46;J&#46; Cooper"
                            1 => "V&#46;R&#46; Harris"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.5694/mja16.00516"
                      "Revista" => array:6 [
                        "tituloSerie" => "Med J Aust"
                        "fecha" => "2017"
                        "volumen" => "206"
                        "paginaInicial" => "41"
                        "paginaFinal" => "45"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28076744"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A closer look at truncal acne vulgaris&#58; prevalence&#44; severity&#44; and clinical significance"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;Q&#46; Del Rosso"
                            1 => "J&#46;B&#46; Bikowski"
                            2 => "E&#46; Baum"
                            3 => "J&#46; Smith"
                            4 => "S&#46; Hawkes"
                            5 => "V&#46; Benes"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Drugs Dermatol"
                        "fecha" => "2007"
                        "volumen" => "6"
                        "paginaInicial" => "597"
                        "paginaFinal" => "600"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17668525"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Acne and quality of life - impact and management"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "U&#46; Gieler"
                            1 => "T&#46; Gieler"
                            2 => "J&#46;P&#46; Kupfer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.13191"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2015"
                        "volumen" => "29"
                        "paginaInicial" => "12"
                        "paginaFinal" => "14"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26059729"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Challenges and solutions in oral isotretinoin in acne&#58; reflections on 35 years of experience"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "V&#46; Bettoli"
                            1 => "A&#46; Guerra-Tapia"
                            2 => "M&#46;I&#46; Herane"
                            3 => "J&#46; Piquero-Mart&#237;n"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/CCID.S234231"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Cosmet Investig Dermatol"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "paginaInicial" => "943"
                        "paginaFinal" => "951"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32021364"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment modalities for Acne"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "L&#46; Fox"
                            1 => "C&#46; Csongradi"
                            2 => "M&#46; Aucamp"
                            3 => "J&#46; du Plessis"
                            4 => "M&#46; Gerber"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3390/molecules21081063"
                      "Revista" => array:4 [
                        "tituloSerie" => "Molecules"
                        "fecha" => "2016"
                        "volumen" => "21"
                        "paginaInicial" => "1063"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Retinoids&#58; a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Khalil"
                            1 => "T&#46; Bardawil"
                            2 => "C&#46; Stephan"
                            3 => "N&#46; Darwiche"
                            4 => "O&#46; Abbas"
                            5 => "A&#46;G&#46; Kibbi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/09546634.2017.1309349"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatolog Treat"
                        "fecha" => "2017"
                        "volumen" => "28"
                        "paginaInicial" => "684"
                        "paginaFinal" => "696"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28318351"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Trifarotene&#58; a current review and perspectives in dermatology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:8 [
                            0 => "T&#46; Cosio"
                            1 => "M&#46; Di Prete"
                            2 => "R&#46; Gaziano"
                            3 => "C&#46; Lanna"
                            4 => "A&#46; Orlandi"
                            5 => "P&#46; Di Francesco"
                            6 => "L&#46; Bianchi"
                            7 => "E&#46; Campione"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3390/biomedicines9030237"
                      "Revista" => array:5 [
                        "tituloSerie" => "Biomedicines"
                        "fecha" => "2021"
                        "volumen" => "9"
                        "paginaInicial" => "237"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33652835"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "U&#46;S&#46; Food and Drug Administration&#46; Novel drug approvals for 2019&#46; Silver Spring&#58; FDA&#59; 2019&#46; Available from&#58; <a target="_blank" href="https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019">https&#58;&#47;&#47;www&#46;fda&#46;gov&#47;drugs&#47;new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products&#47;novel-drug-approvals-2019</a>&#46; &#91;Accessed 8 March 2021&#93;&#46;"
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Heads of Medicine Agencies&#46; Details of Product Name in the RMS&#58; Aklief&#46; Available from&#58; <a target="_blank" href="https://mri.cts-mrp.eu/Human/Product/Details/58971">https&#58;&#47;&#47;mri&#46;cts-mrp&#46;eu&#47;Human&#47;Product&#47;Details&#47;58971</a>&#46; &#91;Accessed 25 May 2021&#93;&#46;"
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management of acne&#58; Canadian clinical practice guideline"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Y&#46; Asai"
                            1 => "A&#46; Baibergenova"
                            2 => "M&#46; Dutil"
                            3 => "S&#46; Humphrey"
                            4 => "P&#46; Hull"
                            5 => "C&#46; Lynde"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1503/cmaj.140665"
                      "Revista" => array:6 [
                        "tituloSerie" => "CMAJ"
                        "fecha" => "2016"
                        "volumen" => "188"
                        "paginaInicial" => "118"
                        "paginaFinal" => "126"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26573753"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Understanding truncal acne&#58; a practical guide to diagnosis and management"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "C&#46;W&#46; Liu"
                            1 => "J&#46; Tan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Skin Therapy Lett"
                        "fecha" => "2017"
                        "volumen" => "12"
                        "paginaInicial" => "1"
                        "paginaFinal" => "7"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18227953"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Truncal acne&#44; what do we know&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "B&#46; Dr&#233;no"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.16634"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2020"
                        "volumen" => "34"
                        "paginaInicial" => "2241"
                        "paginaFinal" => "2246"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32421879"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-&#947; agonist trifarotene"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Aubert"
                            1 => "D&#46; Piwnica"
                            2 => "B&#46; Bertino"
                            3 => "S&#46; Blanchet-R&#233;thor&#233;"
                            4 => "I&#46; Carlavan"
                            5 => "S&#46; D&#233;ret"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.16719"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2018"
                        "volumen" => "179"
                        "paginaInicial" => "442"
                        "paginaFinal" => "456"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29974453"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Randomized phase 3 evaluation of trifarotene 50 &#956;g&#47;g cream treatment of moderate facial and truncal acne"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Tan"
                            1 => "D&#46; Thiboutot"
                            2 => "G&#46; Popp"
                            3 => "M&#46; Gooderham"
                            4 => "C&#46; Lynde"
                            5 => "J&#46; Del Rosso"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2019.02.044"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2019"
                        "volumen" => "80"
                        "paginaInicial" => "1691"
                        "paginaFinal" => "1699"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30802558"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term safety and efficacy of trifarotene 50 &#956;g&#47;g cream&#44; a first-in-class RAR-&#947; selective topical retinoid&#44; in patients with moderate facial and truncal acne"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "U&#46; Blume-Peytavi"
                            1 => "J&#46; Fowler"
                            2 => "L&#46; Kem&#233;ny"
                            3 => "Z&#46; Draelos"
                            4 => "F&#46; Cook-Bolden"
                            5 => "T&#46; Dirschka"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.15794"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2020"
                        "volumen" => "34"
                        "paginaInicial" => "166"
                        "paginaFinal" => "173"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Subject satisfaction with trifarotene 50 &#956;g&#47;g cream in the treatment of facial and truncal acne vulgaris&#58; a case series"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46;M&#46; Johnson"
                            1 => "R&#46; Chavda"
                            2 => "J&#46;C&#46; DuBois"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s13555-020-00417-4"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther &#40;Heidelb&#41;"
                        "fecha" => "2020"
                        "volumen" => "10"
                        "paginaInicial" => "1165"
                        "paginaFinal" => "1173"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "How to increase adherence and compliance in acne treatment&#63; A combined strategy of SMS and visual instruction leaflet"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Donnarumma"
                            1 => "D&#46; Fattore"
                            2 => "V&#46; Greco"
                            3 => "M&#46; Ferrillo"
                            4 => "M&#46; Vastarella"
                            5 => "P&#46; Chiodini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000502575"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatology"
                        "fecha" => "2019"
                        "volumen" => "235"
                        "paginaInicial" => "463"
                        "paginaFinal" => "470"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31586999"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack566195"
        "titulo" => "Acknowledgments"
        "texto" => "<p id="par0075" class="elsevierStylePara elsevierViewall">The authors would like to thank Sonia Romero &#40;scientific advisor&#44; Meisys&#41; for her support in writing this article&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/15782190/0000011200000010/v1_202111080506/S157821902100295X/v1_202111080506/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6152"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Opinion Article"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011200000010/v1_202111080506/S157821902100295X/v1_202111080506/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S157821902100295X?idApp=UINPBA000044"
]

Article information

ISSN: 15782190
Original language: English

DOI:10.1016/j.adengl.2021.04.005

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	11	13	24
2024 October	109	54	163
2024 September	123	41	164
2024 August	145	56	201
2024 July	122	50	172
2024 June	116	36	152
2024 May	122	43	165
2024 April	99	37	136
2024 March	103	44	147
2024 February	85	45	130
2024 January	114	46	160
2023 December	88	26	114
2023 November	110	41	151
2023 October	81	38	119
2023 September	88	38	126
2023 August	80	24	104
2023 July	87	59	146
2023 June	80	31	111
2023 May	104	45	149
2023 April	109	32	141
2023 March	104	50	154
2023 February	58	36	94
2023 January	46	30	76
2022 December	72	60	132
2022 November	55	49	104
2022 October	38	28	66
2022 September	29	48	77
2022 August	26	44	70
2022 July	29	45	74
2022 June	47	46	93
2022 May	173	50	223
2022 April	209	92	301
2022 March	253	103	356
2022 February	248	62	310
2022 January	207	72	279
2021 December	199	97	296
2021 November	201	99	300
2021 October	65	61	126

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter